Ri Cui
Overview
Explore the profile of Ri Cui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin H, Sui H, Yu Y, Xie C, Shen Y, Cheng L, et al.
Eur J Pharmacol
. 2025 Feb;
994:177378.
PMID: 39952584
Lung cancer represents one of the most lethal malignancies, characterized by the highest incidence and mortality rates globally. Cisplatin-based chemotherapy exerts powerful anti-tumor activities in lung cancer, whereas its clinical...
2.
Liang Y, Lin H, Jiang Z, Zhao Q, Cui R, Li S
Discov Oncol
. 2025 Jan;
16(1):103.
PMID: 39883203
No abstract available.
3.
Zhao Q, Zhang Y, Liu J, Chen P, Onga A, Cho N, et al.
Front Pharmacol
. 2025 Jan;
15():1532695.
PMID: 39850563
Background: Polydatin (3,4',5-trihydroxy-3-β-d-glucopyranoside, PD) is known for its antioxidant and anti-inflammatory properties. Oxaliplatin (OXA)-based chemotherapy is the first-line treatment for metastatic and recurrent colorectal cancer (CRC). However, the lack of...
4.
Liang Y, Lin H, Jiang Z, Zhao Q, Cui R, Li S
Discov Oncol
. 2024 Oct;
15(1):603.
PMID: 39472327
Homeobox B8 (HOXB8) belongs to the HOX family and was essential to the development of colorectal carcinoma. Among the prevalent monoclonal antibodies for treating RAS/BRAF wild-type metastatic colorectal cancer (mCRC)...
5.
Wu T, Yu Y, Tu X, Ye L, Wang J, Xie C, et al.
J Ethnopharmacol
. 2024 Aug;
336:118754.
PMID: 39208999
Ethnopharmacological Relevance: Tubeimoside-I (TBM) promotes various cancer cell death by increasing the reactive oxygen species (ROS) production. However, the specific molecular mechanisms of TBM and its impact on oxaliplatin-mediated anti-CRC...
6.
Wu S, Zhao Q, Liu S, Kuang J, Zhang J, Onga A, et al.
Int J Oncol
. 2024 Jun;
65(2).
PMID: 38873997
Non‑small cell lung cancer (NSCLC) is one of the major causes of cancer‑related death worldwide. Cisplatin is a front‑line chemotherapeutic agent in NSCLC. Nevertheless, subsequent harsh side effects and drug...
7.
Shen X, Xia Y, Lu H, Zheng P, Wang J, Chen Y, et al.
Biomed Pharmacother
. 2024 Apr;
174:116507.
PMID: 38565059
Thioredoxin reductase 1 (TrxR1) has emerged as a promising target for cancer therapy. In our previous research, we discovered several new TrxR1 inhibitors and found that they all have excellent...
8.
Ni L, Zhu X, Zhao Q, Shen Y, Tao L, Zhang J, et al.
Neoplasia
. 2024 Mar;
51:100991.
PMID: 38507887
Dihydroartemisinin (DHA) exerts an anti-tumor effect in multiple cancers, however, the molecular mechanism of DHA and whether DHA facilitates the anti-tumor efficacy of cisplatin in non-small cell lung cancer (NSCLC)...
9.
Zheng P, Xia Y, Shen X, Lu H, Chen Y, Xu C, et al.
Int J Biol Sci
. 2024 Jan;
20(1):249-264.
PMID: 38164168
Lung cancer is one of the most lethal diseases in the world. Although there has been significant progress in the treatment of lung cancer, there is still a lack of...
10.
Qiu C, Shen X, Lu H, Chen Y, Xu C, Zheng P, et al.
Cell Death Discov
. 2023 Oct;
9(1):375.
PMID: 37833257
Colon cancer is a major cause of cancer-related death. Despite recent improvements in the treatment of colon cancer, new strategies to improve the overall survival of patients are urgently needed....